Outlier Patients in Cancer Drug Trials Could Personalize Treatment
No cancer is like any other, so it’s no surprise that there’s a lot of variability in how patients respond to cancer drugs. This variability creates a challenge for drug developers: A compound can fail in clinical trials if it does not reverse or at least stall disease progression in a significant percentage of patients, even if it greatly helps some.
Researchers at Memorial Sloan-Kettering Cancer Center in New York examined one such case in a clinical trial of a drug called everolimus. While most patients in the trial were not helped by the drug, one did experience a remarkable recovery. The metastatic bladder cancer of this patient disappeared after a few months on everolimus.
By comparing the genome of this patient’s cancer to his or her healthy genome, the researchers identified a mutation in a gene known to be linked to everolimus’ molecular target. They then looked for mutations in the same gene in 13 other patients involved in the trial. Of the four additional patients with mutations in that gene, three had shown minor positive responses to everolimus, the team reports today in Science.
The authors write that the results show that tumor genome sequencing can identify previously unrecognized biomarkers for drug response in solid tumors. They also suggest that the genomes of tumors from “outlier” patients, who respond to a drug when many others don’t, may provide clues for identifying other patients who could also be helped by the treatment
“Although single patient anecdotes are often dismissed as failing to provide meaningful clinical evidence, this example illustrates the potential for such cases to inform future clinical development of drugs in molecularly defined populations.”
Keep Reading
Most Popular

Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.